EPI

First Wave BioPharma, Inc. Announces Private Placement

Retrieved on: 
Monday, November 21, 2022
Digestion, Fats, Act, FW, Patient, CP, Nutrient, Exocrine pancreatic insufficiency, CF, Exercise, BOCA, Niclosamide, Security (finance), Sale, Ulcerative colitis, Cystic fibrosis, EPI, First wave, Clinical trial, Regulation D, Acquisition

The Company has agreed to call a special meeting of stockholders to seek the required stockholder approval.

Key Points: 
  • The Company has agreed to call a special meeting of stockholders to seek the required stockholder approval.
  • H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
  • First Wave BioPharma is a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases.
  • These forward-looking statements are subject to risks and uncertainties including, among other things, the completion of the private placement, the satisfaction of customary closing conditions related to the private placement and the intended use of proceeds from the private placement.

First Wave BioPharma Chairman and CEO Issues Letter to Stockholders

Retrieved on: 
Wednesday, November 16, 2022
Conference, Food, PERT, IND, Patient, CP, Exocrine pancreatic insufficiency, CF, Food and Drug Administration, BOCA, Capsule, Letter, Cystic fibrosis, EPI, First wave, Investigational New Drug, Stomach, CFA, FDA, Pharmaceutical industry

BOCA RATON, Fla., Nov. 16, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (First Wave BioPharma or the Company), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that James Sapirstein, Chairman, President and CEO of First Wave BioPharma, has issued a Letter to Stockholders providing an update on the Companys clinical programs and recent events.

Key Points: 
  • BOCA RATON, Fla., Nov. 16, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (First Wave BioPharma or the Company), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that James Sapirstein, Chairman, President and CEO of First Wave BioPharma, has issued a Letter to Stockholders providing an update on the Companys clinical programs and recent events.
  • CFA greater than 80% is the recognized threshold for achieving therapeutic benefit in patients with EPI associated with CF and CP.
  • We also restructured our obligations to the former stockholders of First Wave Bio, Inc. which eliminated $10 million of fixed liabilities from our balance sheet.
  • We attended the most recent North American Cystic Fibrosis Conference (NACFC) in Philadelphia and met with clinicians, KOLs and patient advocates.

Novan Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, November 14, 2022
FDA, Marketing, Molluscum contagiosum, Food and Drug Administration, Health, Rosacea, Psoriasis, Failure, EPI, Novin, Skin, Webcast, Conference, Dermatology, JAMA Dermatology, NDA, Annual report, Pharmacy, Acquisition, Satō, Safety, Security (finance), SB206, Documentation, Development, Growth, COVID-19, Research, Acne, Risk, Research and development, Patient, Risk management, Renewable energy, Pharmaceutical industry, Lithium, Video game

DURHAM, N.C., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced its financial and operating results for the third quarter ended September 30, 2022 and provided a corporate update. The Company will host a conference call and webcast, today, November 14, 2022, at 8:30 a.m. ET (details below).

Key Points: 
  • ET
    DURHAM, N.C., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (the Company or Novan) (Nasdaq: NOVN), today announced its financial and operating results for the third quarter ended September 30, 2022 and provided a corporate update.
  • Total prescription activity for third quarter 2022:
    37% growth in third quarter year-to-date compared to same period in 2021;
    31% growth in third quarter compared to third quarter 2021; and
    7% decrease in third quarter compared to second quarter 2022.
  • 216% growth in third quarter compared to third quarter 2021, based in part to timing of product launch in the United States; and 14% decrease in third quarter compared to second quarter 2022.
  • 59% growth in third quarter year-to-date compared to same period in 2021;
    78% growth in third quarter compared to third quarter 2021; and
    23% growth in third quarter compared to second quarter 2022.

The Fresh Dolls by World of EPI Releases New Collection with LL COOL J's Global Hip-Hop Platform Rock The Bells

Retrieved on: 
Tuesday, November 22, 2022
MC, John Bell (radio personality), Adult, Commerce, Human, Beauty, DJ, Inclusivism, Radio, Collection, Target, Macy's, Amazon, Partnership, Latinx, Publishing, African Americans, Multimedia, Sirius XM, Culture, Learning, Politics, EPI, Hip hop, Love, Life, Walmart, LL, Rock the Bells, Language, Toy, Nightclub, Walgreens

CHULA VISTA, Calif., Nov. 22, 2022 /PRNewswire/ -- The Fresh Dolls by World of EPI, a leading manufacturer of multicultural dolls and toys, and Rock The Bells, the global lifestyle platform elevating Hip-Hop culture from its roots to the modern day, founded by entertainment icon LL COOL J, today announced the release of a Hip-Hop themed collection available in-store and online at select Walmart locations.

Key Points: 
  • Since the 1970s, Hip-Hop culture has evolved to become a global phenomenon impacting the lives of generations young and old.
  • We are excited to collaborate with Rock The Bells to highlight Hip-Hop culture, which continues to influence and inspire.
  • Visit us at www.rockthebells.com , stream LL COOL J's Rock The Bells Radio on SiriusXM Channel 43 and follow us @RockTheBells - keep it locked.
  • Today, the World of EPI dolls can be found in stores across the globe, including giant retailers like Amazon, Walmart, Target, Macy's, and Walgreens.

The Netherlands, Singapore, and Austria Top EF's Global English Proficiency Index

Retrieved on: 
Tuesday, November 15, 2022
Kate Bell, Central, City, Woman, Union, EF Standard English Test, EF Education First, EF, School, Travel, Education, EPI, EF EPI, Language, News, Tourism

ZURICH, Nov. 15, 2022 /PRNewswire/ -- EF Education First (EF) today released the 2022 edition of its EF English Proficiency Index (EF EPI), analyzing data from 2.1 million non-native English speakers in 111 countries and regions. The Netherlands retained first place, while Singapore surged to second, cracking the top three again since becoming the first ASEAN nation to do so in 2018. 

Key Points: 
  • ZURICH, Nov. 15, 2022 /PRNewswire/ -- EF Education First (EF) today released the 2022 edition of its EF English Proficiency Index (EF EPI), analyzing data from 2.1 million non-native English speakers in 111 countries and regions.
  • "This year's index reflects the pandemic's impact from a concerning decline in English proficiency among young people to unexpectedly high proficiency outside big cities, which has remote work implications," said EF EPI author Kate Bell.
  • - English proficiency improved for adults over 25, with over 40s improving the most.
  • Proficiency among adults 21 25 was unchanged but declined for the 18-20 cohort by a striking 50 points since 2020.

Harris Williams Advises United States Infrastructure Corporation on its Sale of a 50% Stake to Kohlberg & Company

Retrieved on: 
Friday, November 11, 2022
Professional Services, Utilities, Oil, Gas, Energy, Finance, Banking, SIPC, VAT-free imports from the Channel Islands, Sale, Kohlberg & Company, Financial Conduct Authority, Investment, Farringdon Road, SIX Swiss Exchange, Corporate services, Company, Harris Williams & Co., Financial system, Partners Group, HRB, Engineering, PNC, Pleasure, Technology, Solution, View, USIC, FINRA, Registrar, Electric power infrastructure on Bornholm, EPI, LLC, Telecommunication, Bloodhound, M&A, Partnership, NYSE, Water, Arta Industrial Group, Financial services, Sales, Kohlberg

Harris Williams , a global investment bank specializing in M&A advisory services, announces it advised United States Infrastructure Corporation (USIC), a portfolio company of Partners Group, acting on behalf of its clients, on its sale of a 50% stake to Kohlberg & Company (Kohlberg).

Key Points: 
  • Harris Williams , a global investment bank specializing in M&A advisory services, announces it advised United States Infrastructure Corporation (USIC), a portfolio company of Partners Group, acting on behalf of its clients, on its sale of a 50% stake to Kohlberg & Company (Kohlberg).
  • USIC represents another marquee transaction for Harris Williams within the broader infrastructure services sector, said Matt White, a managing director at Harris Williams.
  • It is a pleasure to have partnered again with USIC, added Bob Baltimore, a managing director at Harris Williams.
  • Harris Williams is a trade name under which Harris Williams LLC, Harris Williams & Co. Ltd and Harris Williams & Co. Corporate Finance Advisors GmbH conduct business.

Lyell Immunopharma Presents New Data at SITC Highlighting its Growing Pipeline of T – Cell Reprogramming Technologies and Product Candidates Targeting Solid Tumors

Retrieved on: 
Monday, November 7, 2022
TIL, Company, Private Securities Litigation Reform Act, Research, Genetic, Maintenance, SAN, Stim, EPI, Abstract cell complex, GLOBE, CAR, Cell, Safety, Lyell, Toxic shock syndrome, COVID-19, Nasdaq, Immunotherapy, NR4A3, TCR, Phenotype, Securities and Exchange Commission (Philippines), Forward-looking statement, Technology, Goal, Security (finance), Melanoma, Society, SITC, Patient, ROR1, Vaccine, Pharmaceutical industry, Medical imaging

This includes new preclinical research on the potential to generate more potent T cells to provide durable anti-tumor functions against certain aggressive solid tumor cancers.

Key Points: 
  • This includes new preclinical research on the potential to generate more potent T cells to provide durable anti-tumor functions against certain aggressive solid tumor cancers.
  • Stackable Genetic and Epigenetic Reprogramming Technologies in LYL119, a Second-Generation CAR T-cell therapy targeting ROR1+ solid tumors
    Two presentations describe preclinical data on Lyells new, stackable reprogramming technologies NR4A3 knockout and Stim-R being incorporated in LYL119, a second-generation ROR1 targeting CAR T-cell product candidate.
  • Lyell plans to incorporate these two stackable genetic reprogramming technologies in its new product candidate, LYL119, currently in preclinical development.
  • Lyell is a clinical-stage T-cell reprogramming company dedicated to developing curative cell therapies for patients with solid tumors.

First Wave BioPharma Engages Rho to Manage Phase 2 Clinical Trial of Enhanced Adrulipase Formulation

Retrieved on: 
Monday, October 31, 2022
Biotechnology, U.S. Securities and Exchange Commission, Marketing, Cystic fibrosis, CP, FW, Yarrowia, Acquisition, Compliance, AAPS, Research, CRO, CEO, Patient, Program, CF, ROI, EPI, Capsule, Diarrhea, Niclosamide, Company, Clinical trial, Research Triangle Park, Security (finance), Nutrient, GLOBE, Cystic Fibrosis Foundation, Exocrine pancreatic insufficiency, Food, Fats, NASDAQ, Weight loss, Drug development, BOCA, PERT, Gastrointestinal tract, First wave, Ulcerative colitis, Digestion, Stomach, Pharmaceutical industry, Rho, Facebook

First Wave BioPharma is developing adrulipase as a treatment for exocrine pancreatic insufficiency (EPI) associated with cystic fibrosis (CF) and chronic pancreatitis (CP).

Key Points: 
  • First Wave BioPharma is developing adrulipase as a treatment for exocrine pancreatic insufficiency (EPI) associated with cystic fibrosis (CF) and chronic pancreatitis (CP).
  • Under the agreement, Rho will manage the Phase 2 clinical trial of the microgranule drug delivery formulation of adrulipase.
  • We are eager to evaluate the potential of our new formulation in the proof-of-concept Phase 2 clinical trial, which we expect to initiate before year-end.
  • We look forward to being a valued partner to First Wave BioPharma in the management of the soon-to-be-initiated Phase 2 trial.

Asia Pacific Silicon EPI Wafer Market Report 2022: Continuous Improvements in Silicon-on-Insulator Wafers to Reshape Sector - ResearchAndMarkets.com

Retrieved on: 
Friday, October 28, 2022
Technology, Automotive, Other Manufacturing, Semiconductor, IOT (Internet of Things), Engineering, Chemicals, Plastics, Automotive Manufacturing, Other Technology, Other Defense, Manufacturing, Other Automotive, 5G, Defense, Mobile, Wireless, Hardware, Consumer Electronics, Gallium, Silicon carbide, Electronics, Health, Epitaxy, CAGR, Growth, Center for Urban and Regional Analysis, Silicon, DC, EPI, COVID-19, Efficiency, Gallium nitride, MEMS, Gallium arsenide, Tissue paper, Borosilicate glass, Si

The "Asia Pacific Silicon EPI Wafer Market Forecast to 2028 - COVID-19 Impact and Regional Analysis - Wafer Size, Application, End User, and Type" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Asia Pacific Silicon EPI Wafer Market Forecast to 2028 - COVID-19 Impact and Regional Analysis - Wafer Size, Application, End User, and Type" report has been added to ResearchAndMarkets.com's offering.
  • Continuous advancements in AI-based GaN wafers are providing lucrative opportunities for the future growth of the silicon EPI wafer market.
  • The Asia-Pacific silicon EPI wafer market is segmented on the basis of wafer size, application, end user, type, and country.
  • Based on country, the Asia Pacific silicon EPI wafer market is segmented into Taiwan, China, India, Japan, South Korea, and Rest of Asia Pacific.

Data Silicon Awards: Kalray Wins Gold Innovation Award, Public Award and Bronze Grand Prize With Its New Generation DPU Processor

Retrieved on: 
Wednesday, October 26, 2022
Technology, Mobile, Wireless, Other Technology, Professional Services, Software, Internet, Hardware, Data Management, Other Professional Services, Automotive industry, Efficiency, General manager, DPU, Laboratory, Architecture, Central processing unit, Entertainment, Renault–Nissan–Mitsubishi Alliance, CEA, CEA-Leti: Laboratoire d'électronique des technologies de l'information, Data, NXP Semiconductors, Technology, Data management, Partnership, European Initiative Prize, Solution, Software, Acquisition, Scientific method, Graphics processing unit, AI, Ecosystem, Edge computing, Silicon, DNA, Dell Technologies, Bronze Award, Heart, List of life sciences, NXP, VMware, Semiconductor, EPI, Video game console, Network equipment, Kalray, Cloud

Organized as part of the Silicon Day Data, the Silicon Data Awards recognize the best data projects, solutions and innovations in the IT and tech world.

Key Points: 
  • Organized as part of the Silicon Day Data, the Silicon Data Awards recognize the best data projects, solutions and innovations in the IT and tech world.
  • These awards once again recognize Kalrays unique technology, which also won an award at the Flash Memory Summit last August.
  • With its patented 80-core architecture, Kalray's DPU processor manages multiple data streams in parallel and without bottlenecks.
  • Kalrays DPU is a low-power, high-performance programmable processor dedicated to data-intensive applications for fast-growing markets such as the data center, AI, edge computing, 5G, automotive ...